Trial Profile

Efficacy and Safety of Sitagliptin and Glargine Compared to a Basal-plus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin glargine (Primary) ; Insulin lispro (Primary) ; Sitagliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms SITA-PLUS hospital trial; SITAGLAR-H

Most Recent Events

01 May 2024 Primary endpoint (Change of the mean daily blood glucose levels during hospital) has been met.
01 May 2024 Results assessing the efficacy and safety of basal-plus (BP) insulin regimen with sitagliptin in non-critically ill patients with type 2 diabetes (T2D), published in the Journal of Diabetes and its Complications
21 Sep 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com